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Mitochondrial Complex I (NADH ubiquinone oxidoreductase) is
the ﬁrst of three energy transducing enzymes of the respiratory chain.
Loss of Complex I activity is associated with ageing, neu-
rodegeneration and ischaemia–reperfusion injury rendering further
investigation of Complex I catalytic regulation pertinent.
The mammalian enzyme can exist in two conformationally-
distinct, interconvertible forms — active (A) and dormant, de-active
(D). These forms have been described in intact cells [1] and recently
in various tissues in ischaemia (as further described in [2] of this
issue). The high activation energy of 270 kJ/mol of the A to D
transition [3] indicates the occurrence of major conformational
changes in Complex I.
In this work we have developed an approach to analyse the
differences in relative location of Complex I subunits in the A and the
D-form. Using preparation of bovine heart submitochondrial particles
(SMP), we have established the conditions in which the majority of
the enzyme is present in the D-form or, alternatively, the majority is
in the A-form. Several hetero- and homobifunctional crosslinkers of
different length were used. Complex I was isolated using Blue Native
electrophoresis and subunits were separated using 2D SDS PAGE. The
crosslinking products were analysed by MS/MS and based on the
presented data possible differences in the relative location of
Complex I subunits are discussed.
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Complex I catalyses the two electron oxidation of NADH by
quinone, to drive proton pumping across an energy transducing
membrane. Much work on complex I has been done using sub-
mitochondrial particles derived from the inner membrane of
mitochondria, these have the active sites of the respiratory complexes
facing the bulk solution to allow the direct access of substrates. An
analogous system can be created using Paracoccus denitriﬁcans, based
on osmotic rupture of lysozyme digested cells. P. denitriﬁcans is an
ideal model for mammalian complex I as all the subunits can be
mutated via genomic manipulation; additionally, P. denitriﬁcans
complex I is closely related to the eukaryotic enzyme. Monitoring
NADH at 340 nm is easy, but monitoring proton pumping is much
harder; available methods are either only semi-quantitative or have a
response time that is too slow to follow the pre-steady state reactions
that build the proton motive force. We have developed a robust
system that allows small changes in pH in the bulk solution outside of
the vesicles to be monitored by using pH probes. Our system allows
NADH oxidation and proton translocation to be monitored alongside
each other; we aim to use changes in these activities induced by
mutagenesis to construct a quantitative model of complex I catalysis.
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Metformin is widely prescribed for the management of type 2
diabetes. It has been proposed to exert its beneﬁcial effects by
inhibiting respiratory complex I in mitochondria; the inhibition has
been proposed to activate AMP kinase, triggering a cascade which
increases glucose uptake, inhibits gluconeogenesis and fatty acid
synthesis in the liver, and regulates insulin synthesis and secretion in
pancreatic islet cells [1,2]. More recently, metformin treatment has
been linked to anticancer beneﬁts [3]. Therefore, it is crucial to
determine precisely how this drug produces its observed effects.
Complex I has been proposed as the primary target of metformin
due to the observed decrease in NADH-linked oxygen consumption in
intact cells, isolated mitochondria and submitochondrial particles
upon metformin treatment [1,4]. However, the molecular mechanism
of inhibition has not yet been deduced. In this work, the effects of
metformin on catalysis by isolated bovine complex I are described
on a molecular level, and the projected impacts and downstream
effects of the inhibition caused by therapeutically-relevant levels are
discussed.
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Mitochondrial complex I catalyses electron transfer from NADH to
ubiquinone and it is the major entry point of substrates to the
respiratory chain. Complex I not only produces O–2 through the auto-
oxidation of ﬂavin-semiquinone, but also it is sensitive to oxidants
and reactive nitrogen species. NO inhibits complex I activity by S-
nitrosylation or Fe-nitrosation. Mitochondrial NO production is
carried out by the mtNOS, a NOS located in mitochondrial inner
membrane. Persichini et al. [1] reported that mtNOS is associated to
Va subunit of cytochrome oxidase. Franco et al. [2] showed that not
only complex IV but also complex I proteins immunoprecipitate with
mtNOS, suggesting direct physical interactions between mtNOS and
complexes I and IV proteins. Therefore, the aim of this work was to
characterize the functional interaction between complex I andmtNOS
using phosphorylating electron transfer particles (ETPH-Mg2+), i.e.
inside-out vesicles, that expose NADH dehydrogenase and mtNOS to
the surrounding medium. ETPH-Mg2+ showed a NAD+ reductase
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activity (14.4±0.9 nmol/min.mg protein) sustained by reversed
electron ﬂow of the respiratory chain when succinate and ATP were
added. This activity was inhibited by the addition of rotenone (88%),
oligomycin (98%), antimycin (77%) andm-CCCP (93%). NO generation
by ETPH-Mg2+ resulted 0.62±0.03 nmol/min.mg protein in optimal
experimental conditions (0.5 mM MgCl2, 0.3 mM KCN). The mtNOS
activity was still detectable (99%) in the absence of an exogenous
electron donor (NADPH) suggesting that NO production could be
supported by electrons derived from the respiratory chain. Rotenone
inhibited mtNOS activity (86%) supported by reversed electron ﬂow,
but it did not inhibit the activity of isolated nNOS indicating that its
inhibitory effect on NO production by ETPH-Mg2+ is due to an
electron ﬂow inhibition and not to a direct action on mtNOS
structure. The dependence of mtNOS activity on metabolic state and
membrane potential, and the physical interaction among mtNOS,
cytochrome oxidase and complex I proteins, support the hypothesis
that mtNOS could interact with complex I proteins using electrons
derived from the respiratory chain for its enzymatic activity.
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Inhibition of the mitochondrial permeability transition pore (PTP)
has proved to be an effective strategy for preventing oxidative stress-
induced cell death, and the pore represents a viable cellular target for
drugs. Here, we report that inhibition of complex I by rotenone is
more effective at PTP inhibition than cyclosporin A (CsA) in tissues
that express low levels of the CsA mitochondrial target, cyclophilin D
(CypD); and, conversely, that tissues in which rotenone does not
affect the PTP are characterized by high levels of expression of CypD
and sensitivity to CsA. Consistent with a regulatory role of complex I
in the PTP-inhibiting effects of rotenone, the concentrations of the
latter required for PTP inhibition precisely match those required to
inhibit respiration; and a similar effect is seen with the antidiabetic
drug metformin, which partially inhibits complex I. Remarkably (i)
genetic ablation of CypD or its displacement with CsA restored PTP
inhibition by rotenone in tissues that are otherwise resistant to its
effects; and (ii) rotenone did not inhibit the PTP unless phosphate
was present, in striking analogy with the phosphate requirement for
the inhibitory effects of CsA. These results indicate that inhibition of
complex I by rotenone or metformin and displacement of CypD by
CsA affect the PTP through a common mechanism; and that cells can
modulate their PTP response to complex I inhibition by modifying the
expression of CypD, a ﬁnding that has major implications for pore
modulation in vivo.
doi:10.1016/j.bbabio.2012.06.150
6P11
The protease inhibitor SERPINB3 inhibits permeability transition
pore through the regulation of mitochondrial
Complex I ROS production
Francesco Ciscato, Marco Sciacovelli, MariaGrazia Ruvoletto, Paolo
Bernardi, Andrea Rasola, Patrizia Pontisso
Clinical and Experimental Medicine and Department of Biomedical
Sciences, Viale G. Colombo 3, I-32128 Padua, Italy
E-mail: francesco.ciscato@gmail.com
SERPINB3 (SB3) is a member of the family of ov-serin-protease
inhibitors overexpressed in epithelial and hepatic tumors. We have
found that a fraction of SB3 is located inmitochondria of hepatoma cells.
In order to understand whether the mitochondrial location of SB3 is
somehow connected to biological traits relevant to the neoplastic
phenotype, we have addressed the possibility that SB3 is part of the
anti-apoptotic machinery that hallmarks most tumor types. In partic-
ular, inhibition of the mitochondrial permeability transition pore (PTP)
constitutes a point of no-return in cell commitment to death, and its
inhibition is believed to play a primary role in tumor cell survival and
resistance to anticancer drugs.
We have found that stable transfection with either the human
wild type SB3 or the protease-dead DH-SB3 confers protection to
death induced in hepatoma cells either with the ﬁrst-line chemo-
therapeutic Cisplatin or with the PTP inducer EM20-25. Treatment
with the antioxidant compound N-acetyl cysteine could abrogate
death induction, and SB3-expressing cells show lower ROS levels both
in basal conditions and after EM20-25 treatment. Notably, we observe
that SB3 co-immunoprecipitates with respiratory chain Complex I,
one of the major sites of superoxide production in cells, and that this
interaction results in inhibition of Complex I activity.
Taken together, these results indicate that SB3 protects hepatoma
cells from death induced by oxidative stress through down-modulation
of Complex I and the ensuing PTP desensitization, paving the way for
the identiﬁcation of novel anti-neoplastic strategies.
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Endometrial carcinoma (EC) is a common neoplasia of the female
genital tract. This cancer may be grouped into two subsets, namely
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